Cellyan Biotechnology
HKPD
2 hedge funds and large institutions have $17.8K invested in Cellyan Biotechnology in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 4 closing their positions.
0.56% less ownership
Funds ownership: 0.67% → 0.11% (-0.56%)
67% less funds holding
Funds holding: 6 → 2 (-4)
81% less capital invested
Capital invested by funds: $93.5K → $17.8K (-$75.7K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$26.6K |
| 2 |
Jane Street
New York
|
-$21.8K |
| 3 |
VNA
Valley National Advisers
Bethlehem,
Pennsylvania
|
-$16K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$13.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$399 |
HKPD Hedge Fund Activity: Q3 2025 in Review
2 of the 7,645 institutional investors tracked by Wall St. Rank reported a position in Cellyan Biotechnology (HKPD) for Q3 2025, worth a combined $17.8K — down 81% from $93.5K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of HKPD and 0 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was UBS Group, cutting an estimated $26.6K.
- 2 institutional investors held Cellyan Biotechnology (HKPD) as of Q3 2025, down from 6 in Q2 2025.
- Funds reported $17.8K of Cellyan Biotechnology stock for Q3 2025, down 81% quarter-over-quarter.
- 0 funds opened new Cellyan Biotechnology positions in Q3 2025 and 4 closed out, a net change of -4 holders.
- The largest Cellyan Biotechnology seller in Q3 2025 was UBS Group, an estimated $26.6K sold.
Based on aggregated 13F filings for Q3 2025.